1 – 20 of 20
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ε4 allele
(
- Contribution to journal › Article
- 2012
-
Mark
Age and diagnostic performance of Alzheimer disease CSF biomarkers
(
- Contribution to journal › Article
- 2011
-
Mark
Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
(
- Contribution to journal › Article
- 2010
-
Mark
The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease
(
- Contribution to journal › Article
- 2008
-
Mark
Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease
(
- Contribution to journal › Article
- 2006
-
Mark
CSF Biomarkers for Alzheimer's Disease: Levels of beta-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival.
(
- Contribution to journal › Article
-
Mark
Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment
(
- Contribution to journal › Article
- 2003
-
Mark
Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients
(
- Contribution to journal › Article
- 2002
-
Mark
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors
(
- Contribution to journal › Article
- 2001
-
Mark
Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders
(
- Contribution to journal › Article
-
Mark
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values
(
- Contribution to journal › Article
-
Mark
Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype
(
- Contribution to journal › Article
- 2000
-
Mark
Measurement of apolipoprotein E (apoE) in cerebrospinal fluid
(
- Contribution to journal › Article
-
Mark
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma
(
- Contribution to journal › Article
-
Mark
No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression
(
- Contribution to journal › Article
- 1999
-
Mark
Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
(
- Contribution to journal › Article